IL270267A - - Google Patents

Info

Publication number
IL270267A
IL270267A IL27026719A IL27026719A IL270267A IL 270267 A IL270267 A IL 270267A IL 27026719 A IL27026719 A IL 27026719A IL 27026719 A IL27026719 A IL 27026719A IL 270267 A IL270267 A IL 270267A
Authority
IL
Israel
Application number
IL27026719A
Other languages
English (en)
Other versions
IL270267B2 (en
IL270267B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL270267A publication Critical patent/IL270267A/en
Publication of IL270267B1 publication Critical patent/IL270267B1/en
Publication of IL270267B2 publication Critical patent/IL270267B2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL270267A 2017-05-06 2018-05-04 Methods of treating eye disorders with aplnr antagonists and vegf inhibitors IL270267B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762502621P 2017-05-06 2017-05-06
PCT/US2018/031255 WO2018208625A1 (en) 2017-05-06 2018-05-04 Methods of treating eye disorders with aplnr antagonists and vegf inhibitors

Publications (3)

Publication Number Publication Date
IL270267A true IL270267A (cg-RX-API-DMAC7.html) 2019-12-31
IL270267B1 IL270267B1 (en) 2024-02-01
IL270267B2 IL270267B2 (en) 2024-06-01

Family

ID=62555166

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270267A IL270267B2 (en) 2017-05-06 2018-05-04 Methods of treating eye disorders with aplnr antagonists and vegf inhibitors

Country Status (9)

Country Link
EP (1) EP3618876A1 (cg-RX-API-DMAC7.html)
JP (1) JP7161494B2 (cg-RX-API-DMAC7.html)
KR (1) KR102667021B1 (cg-RX-API-DMAC7.html)
CN (1) CN110709104A (cg-RX-API-DMAC7.html)
AU (1) AU2018266324B2 (cg-RX-API-DMAC7.html)
EA (1) EA201992630A1 (cg-RX-API-DMAC7.html)
IL (1) IL270267B2 (cg-RX-API-DMAC7.html)
MX (1) MX389729B (cg-RX-API-DMAC7.html)
WO (1) WO2018208625A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021231255A1 (en) 2020-05-11 2021-11-18 Ascava, Inc. Exploiting locality of prime data for efficient retrieval of data that has been losslessly reduced using a prime data sieve
CN115920057A (zh) * 2023-01-03 2023-04-07 中国科学院合肥物质科学研究院 靶向aplnr蛋白棕榈酰化修饰的多肽及其在癌痛治疗中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
JP2006523209A (ja) 2003-03-12 2006-10-12 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ アペリン組成物によって血管新生を調節するための方法
WO2006088650A2 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
RU2432155C3 (ru) 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US9156911B2 (en) 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
CA2861062A1 (en) 2012-01-23 2013-08-01 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
EP2836510A1 (en) 2012-04-11 2015-02-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides as apelin inhibitors and uses thereof
JP5775851B2 (ja) 2012-06-27 2015-09-09 東京エレクトロン株式会社 塗布装置および塗布液充填方法
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
US9353163B2 (en) * 2013-03-14 2016-05-31 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
CN105916881A (zh) 2013-11-20 2016-08-31 瑞泽恩制药公司 Aplnr调节剂及其用途
US10247722B2 (en) 2014-03-20 2019-04-02 Centre National De La Recherche Scientifique (Cnrs) Use of compounds inhibiting apelin / APJ / GP130 signaling for treating cancer
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
RU2763916C2 (ru) * 2015-09-23 2022-01-11 Дженентек, Инк. Оптимизированные варианты анти-vegf антител

Also Published As

Publication number Publication date
JP2020518641A (ja) 2020-06-25
CA3062418A1 (en) 2018-11-15
KR20200004366A (ko) 2020-01-13
MX389729B (es) 2025-03-20
EP3618876A1 (en) 2020-03-11
IL270267B2 (en) 2024-06-01
KR102667021B1 (ko) 2024-05-21
CN110709104A (zh) 2020-01-17
MX2019012985A (es) 2020-01-13
IL270267B1 (en) 2024-02-01
WO2018208625A1 (en) 2018-11-15
JP7161494B2 (ja) 2022-10-26
EA201992630A1 (ru) 2020-04-29
AU2018266324B2 (en) 2024-02-01
AU2018266324A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
IL270267A (cg-RX-API-DMAC7.html)
BR202018014992U2 (cg-RX-API-DMAC7.html)
BR202017025154U2 (cg-RX-API-DMAC7.html)
BR202017021228U2 (cg-RX-API-DMAC7.html)
BR202017020981U2 (cg-RX-API-DMAC7.html)
BR202017017068U2 (cg-RX-API-DMAC7.html)
BR202017016984U2 (cg-RX-API-DMAC7.html)
BR202017016924U2 (cg-RX-API-DMAC7.html)
BR202017012548U2 (cg-RX-API-DMAC7.html)
BR202017011220U2 (cg-RX-API-DMAC7.html)
BR202017010814U2 (cg-RX-API-DMAC7.html)
BR202017010373U2 (cg-RX-API-DMAC7.html)
BR202017009870U2 (cg-RX-API-DMAC7.html)
BR202017006953U2 (cg-RX-API-DMAC7.html)
BR202017004898U2 (cg-RX-API-DMAC7.html)
CN304005542S (cg-RX-API-DMAC7.html)
CN303826083S9 (cg-RX-API-DMAC7.html)
CN303997605S (cg-RX-API-DMAC7.html)
CN303994827S (cg-RX-API-DMAC7.html)
CN303993444S (cg-RX-API-DMAC7.html)
CN303993196S (cg-RX-API-DMAC7.html)
CN303952054S8 (cg-RX-API-DMAC7.html)
CN303949240S9 (cg-RX-API-DMAC7.html)
CN303948614S9 (cg-RX-API-DMAC7.html)
CN304014013S (cg-RX-API-DMAC7.html)